BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29627262)

  • 21. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
    Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
    Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
    Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
    Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.
    Gerken PA; Wolstenhulme JR; Tumber A; Hatch SB; Zhang Y; Müller S; Chandler SA; Mair B; Li F; Nijman SMB; Konietzny R; Szommer T; Yapp C; Fedorov O; Benesch JLP; Vedadi M; Kessler BM; Kawamura A; Brennan PE; Smith MD
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15555-15559. PubMed ID: 28976073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
    Hinohara K; Wu HJ; Vigneau S; McDonald TO; Igarashi KJ; Yamamoto KN; Madsen T; Fassl A; Egri SB; Papanastasiou M; Ding L; Peluffo G; Cohen O; Kales SC; Lal-Nag M; Rai G; Maloney DJ; Jadhav A; Simeonov A; Wagle N; Brown M; Meissner A; Sicinski P; Jaffe JD; Jeselsohn R; Gimelbrant AA; Michor F; Polyak K
    Cancer Cell; 2018 Dec; 34(6):939-953.e9. PubMed ID: 30472020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of JMJD7 inhibitors with the aid of virtual screening and bioactivity evaluation.
    Zhang W; Li K; Wang T; Wu M; Li L
    Bioorg Med Chem Lett; 2021 Aug; 45():128139. PubMed ID: 34048880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of KDM5A in human cancer.
    Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
    J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
    Baby S; Gurukkala Valapil D; Shankaraiah N
    Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
    Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
    Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
    Xhabija B; Kidder BL
    Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
    Hamada S; Suzuki T; Mino K; Koseki K; Oehme F; Flamme I; Ozasa H; Itoh Y; Ogasawara D; Komaarashi H; Kato A; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Med Chem; 2010 Aug; 53(15):5629-38. PubMed ID: 20684604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological inhibition of KDM5A for cancer treatment.
    Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
    Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
    Wu X; Fang Z; Yang B; Zhong L; Yang Q; Zhang C; Huang S; Xiang R; Suzuki T; Li LL; Yang SY
    Bioorg Med Chem Lett; 2016 May; 26(9):2284-8. PubMed ID: 27020306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
    Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
    Sayegh J; Cao J; Zou MR; Morales A; Blair LP; Norcia M; Hoyer D; Tackett AJ; Merkel JS; Yan Q
    J Biol Chem; 2013 Mar; 288(13):9408-17. PubMed ID: 23408432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.
    Gaillard S; Charasson V; Ribeyre C; Salifou K; Pillaire MJ; Hoffmann JS; Constantinou A; Trouche D; Vandromme M
    Biol Open; 2021 May; 10(5):. PubMed ID: 34184733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.